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Spinal muscular atrophy (SMA) is a neurodegenerative disorder that is 
relatively common in humans and is caused by loss of the survival motor 
neuron 1 (SMN1) gene.  SMA is the leading cause of hereditary infant 
mortality by causing anterior horn cell degeneration in the spinal cord 
resulting in trunk and limb paralysis.  The survival motor neuron 2 (SMN2) 
gene is located proximally to the SMN1 gene on chromosome 5q and the two 
genes are almost identical. Interestingly, only mutations in SMN1 cause SMA, 
whereas mutations in SMN2 have no clinical consequence. A differential pre-
mRNA splicing event results in SMN2s failure to compensate fully for SMN1 
mutations. Exon 7 is excised during SMN2 RNA splicing and this causes 
expression of a non-functional gene product.  SMN2 produces the SMN protein 
at low levels (~10% compared to SMN1) but not enough to compensate for the 
loss of SMN1. Previous studies have shown that the use of antisense 
oligonucleotides can significantly decrease recognition of the 3’ splice site 
of exon 8, resulting in an increase in increased levels exon 7 inclusion in 
SMN2-derived transcripts. Here, we have developed in vivo expression vectors 
that generate antisense oligonucleotides spanning two regions of the SMN2 
transcript: a repressor exon 7 splicing “repressor” region and the exon 8 
splice acceptor site. We are adding a pol III terminating sequence downstream 
of the antisense sequences to ensure that the clones are only making short 
oligos. If successful, these vectors could be used to increase SMN protein 
expression in an SMA context and may open a new area of SMA therapeutics, as 
well as providing a fundamental basis for treating other genetic disorders 
where splicing events are the main cause of disease.  
 
